Back to Search
Start Over
Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?
- Source :
-
Cephalalgia . May2024, Vol. 44 Issue 5, p1-5. 5p. - Publication Year :
- 2024
-
Abstract
- Background: The development and approval of antibodies targeting calcitonin gene-related peptide or its receptor mark a revolutionary era for preventive migraine treatment. Real-world evidence sheds light on rare, stigmatized or overlooked side effects of these drugs. One of these potential side effects is sexual dysfunction. Case reports: We present two cases of one 42-year-old and one 45-year-old female patient with chronic migraine who both reported sexual dysfunction as a possible side effect of treatment with galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide. Discussion: As calcitonin gene-related peptide is involved in vaginal lubrication as well as genital sensation and swelling, inhibiting the calcitonin gene-related peptide pathway may lead to sexual dysfunction as a potential side effect. Conclusion: Sexual dysfunction in female migraine patients might be a rare and overlooked side effect of monoclonal antibodies targeting the calcitonin gene-related peptide pathway. Considering the discomfort and stigma surrounding both migraine and sexual dysfunction, we advocate for an open attitude and awareness among clinicians toward such side effects. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 03331024
- Volume :
- 44
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Cephalalgia
- Publication Type :
- Academic Journal
- Accession number :
- 177650823
- Full Text :
- https://doi.org/10.1177/03331024241248837